Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 167

1.

Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review.

Kretschmer A, Ploussard G, Heidegger I, Tsaur I, Borgmann H, Surcel C, Mathieu R, de Visschere P, Valerio M, van den Bergh RCN, Marra G, Thibault C, Ost P, Gandaglia G, Tilki D; EAU-YAU Prostate Cancer Working Party.

Eur Urol Focus. 2020 Feb 20. pii: S2405-4569(20)30064-X. doi: 10.1016/j.euf.2020.01.017. [Epub ahead of print] Review.

PMID:
32089495
2.

Same-day discharge surgery for robot-assisted radical prostatectomy in the era of ERAS and prehabilitation pathways: a contemporary, comparative, feasibility study.

Ploussard G, Almeras C, Beauval JB, Gautier JR, Loison G, Salin A, Tollon C.

World J Urol. 2020 Feb 17. doi: 10.1007/s00345-020-03119-w. [Epub ahead of print]

PMID:
32065277
3.

Independent Evaluation of the Respective Predictive Values for High-Grade Prostate Cancer of Clinical Information and RNA Biomarkers after Upfront MRI and Image-Guided Biopsies.

Roumiguié M, Ploussard G, Nogueira L, Bruguière E, Meyrignac O, Lesourd M, Péricart S, Malavaud B.

Cancers (Basel). 2020 Jan 24;12(2). pii: E285. doi: 10.3390/cancers12020285.

4.

Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading Prediction.

Ploussard G, Beauval JB, Renard-Penna R, Lesourd M, Manceau C, Almeras C, Gautier JR, Loison G, Portalez D, Salin A, Soulié M, Tollon C, Malavaud B, Roumiguié M.

J Clin Med. 2020 Jan 15;9(1). pii: E225. doi: 10.3390/jcm9010225.

5.

Improvement of the intermediate risk prostate cancer sub-classification by integrating MRI and fusion biopsy features.

Roumiguie M, Lesourd M, Zgheib J, Tollon C, Salin A, Alméras C, Doumerc N, Thoulouzan M, Soulié M, Gautier JR, Loison G, Assoun J, Vacher A, Aziza R, Malavaud B, Beauval JB, Ploussard G.

Urol Oncol. 2020 Jan 13. pii: S1078-1439(19)30505-8. doi: 10.1016/j.urolonc.2019.12.018. [Epub ahead of print]

PMID:
31948932
6.

Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies.

Ploussard G, Beauval JB, Lesourd M, Almeras C, Assoun J, Aziza R, Gautier JR, Loison G, Portalez D, Salin A, Tollon C, Soulié M, Malavaud B, Roumiguié M.

Urology. 2019 Dec 30. pii: S0090-4295(19)31124-0. doi: 10.1016/j.urology.2019.10.039. [Epub ahead of print]

PMID:
31899229
7.

Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery.

Ploussard G, Manceau C, Beauval JB, Lesourd M, Almeras C, Gautier JR, Loison G, Salin A, Soulié M, Tollon C, Malavaud B, Roumiguié M.

World J Urol. 2019 Dec 14. doi: 10.1007/s00345-019-03053-6. [Epub ahead of print]

PMID:
31838560
8.

Hereditary prostate cancer - Primetime for genetic testing?

Heidegger I, Tsaur I, Borgmann H, Surcel C, Kretschmer A, Mathieu R, Visschere P, Valerio M, van den Bergh RCN, Ost P, Tilki D, Gandaglia G, Ploussard G; EAU-YAU Prostate Cancer Working Party.

Cancer Treat Rev. 2019 Dec;81:101927. doi: 10.1016/j.ctrv.2019.101927. Epub 2019 Nov 11. Review.

PMID:
31783313
9.

Re: Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.

Ploussard G.

Eur Urol. 2020 Mar;77(3):393. doi: 10.1016/j.eururo.2019.10.014. Epub 2019 Nov 12. No abstract available.

PMID:
31727449
10.

Robotic versus open radical cystectomy throughout the learning phase: insights from a real-life multicenter study.

Lenfant L, Campi R, Parra J, Graffeille V, Masson-Lecomte A, Vordos D, de La Taille A, Roumiguie M, Lesourd M, Taksin L, Misraï V, Granger B, Ploussard G, Vaessen C, Verhoest G, Rouprêt M.

World J Urol. 2019 Nov 13. doi: 10.1007/s00345-019-02998-y. [Epub ahead of print]

PMID:
31720765
11.

Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study.

Ploussard G, Beauval JB, Lesourd M, Manceau C, Almeras C, Aziza R, Gautier JR, Loison G, Portalez D, Salin A, Tollon C, Soulié M, Malavaud B, Roumiguié M.

World J Urol. 2019 Oct 14. doi: 10.1007/s00345-019-02973-7. [Epub ahead of print]

PMID:
31612251
12.

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.

Thiery-Vuillemin A, Poulsen MH, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Lefresne F, Lukac M, Van Sanden S, Pissart G, Reid A; AQUARiUS Investigators.

Eur Urol. 2020 Mar;77(3):380-387. doi: 10.1016/j.eururo.2019.09.019. Epub 2019 Oct 5.

13.

The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.

Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Roumiguié M, Fossati N, Stabile A, Beauval JB, Malavaud B, Scuderi S, Barletta F, Moschini M, Zamboni S, Rakauskas A, Tian Z, Karakiewicz PI, De Cobelli F, Porpiglia F, Montorsi F, Briganti A.

Eur Urol. 2019 Sep 21. pii: S0302-2838(19)30694-3. doi: 10.1016/j.eururo.2019.09.005. [Epub ahead of print]

PMID:
31547938
14.

Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.

Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Salomon L, Ploussard G, Tilki D; EAU-YAUWP.

J Urol. 2020 Feb;203(2):338-343. doi: 10.1097/JU.0000000000000504. Epub 2019 Aug 22.

PMID:
31437119
15.

Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes.

Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan WS, Kelly JD, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz PI, Rouprêt M, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Lotan Y, Sooriakumaran P, Shariat SF.

J Clin Med. 2019 Aug 9;8(8). pii: E1192. doi: 10.3390/jcm8081192.

16.

Erratum: CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.

Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A, Allory Y, de la Taille A, Salomon DS, Vacherot F.

Oncotarget. 2019 Jun 25;10(41):4247-4248. doi: 10.18632/oncotarget.27038. eCollection 2019 Jun 25.

17.

Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance Imaging.

Ploussard G, Beauval JB, Lesourd M, Almeras C, Assoun J, Aziza R, Gautier JR, Loison G, Portalez D, Salin A, Tollon C, Soulié M, Malavaud B, Roumiguié M.

J Urol. 2019 Dec;202(6):1182-1187. doi: 10.1097/JU.0000000000000418. Epub 2019 Jun 27.

PMID:
31246548
18.

Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.

Ploussard G, Beauval JB, Lesourd M, Almeras C, Assoun J, Aziza R, Gautier JR, Loison G, Portalez D, Salin A, Tollon C, Soulié M, Malavaud B, Roumiguié M.

World J Urol. 2019 Jun 13. doi: 10.1007/s00345-019-02848-x. [Epub ahead of print]

PMID:
31197523
19.

Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes among selected centres in North America and Europe: an international multicentre collaboration.

Zamboni S, Soria F, Mathieu R, Xylinas E, Abufaraj M, D Andrea D, Tan WS, Kelly JD, Simone G, Gallucci M, Meraney A, Krishna S, Konety BR, Antonelli A, Simeone C, Baumeister P, Mattei A, Briganti A, Gallina A, Montorsi F, Rink M, Aziz A, Karakiewicz PI, Rouprêt M, Koupparis A, Scherr DS, Ploussard G, Sooriakumaran P, Shariat SF, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group.

BJU Int. 2019 May 4. doi: 10.1111/bju.14791. [Epub ahead of print]

PMID:
31055865
20.

Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?

Tsaur I, Heidegger I, Kretschmer A, Borgmann H, Gandaglia G, Briganti A, de Visschere P, Mathieu R, Valerio M, van den Bergh R, Ost P, Mirvald C, Tilki D, Ploussard G, Surcel C; EAU-YAU Prostate Cancer Working Party.

Cancer Treat Rev. 2019 May;75:20-26. doi: 10.1016/j.ctrv.2019.03.001. Epub 2019 Mar 11. Review.

PMID:
30875581

Supplemental Content

Loading ...
Support Center